Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920996 · ClinicalTrials.gov registry record · Phase 2
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02920996 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT02920996, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the NTRK gene (an NTRK1, 2, or 3 rearrangement).
Interventions
- DRUG Merestinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2023-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920996
The ClinicalTrials.gov registry entry for NCT02920996 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Merestinib is the first listed.
NCT02920996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920996 about?
NCT02920996 is a clinical study titled "Merestinib In Non-Small Cell Lung Cancer And Solid Tumors". This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon 14 mutation); or as a treatment for solid tumors that have an alteration in the NTRK gene (an NTRK1, 2,...
What is the current status of trial NCT02920996?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-11-11. Estimated completion is 2023-10.
What interventions are being tested in trial NCT02920996?
The interventions under investigation include: Merestinib (DRUG).
Who is sponsoring clinical trial NCT02920996?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.